The present invention provides a treatment for Hepatitis C virus infection patients of different IL28B gentoypes. The invention therefore provides for the prevention of the clinical sequelae of Hepatitis C viral infections. The present invention also provides a treatment for liver damage and liver inflammation. In one embodiment the invention provides a therapeutic regimen comprising administering to a patient having IL28B genotype CC, CT or TT, VX-222, or a pharmaceutically acceptable salt thereof.
